- Thrombolytic drugs: If one doesn't work, try another. // Geriatrics;Aug94, Vol. 49 Issue 8, p58
Presents the summary of findings from the study entitled `Differences in Clot Lysis among Patients Demonstrated in vitro with Three Thrombolytic Agents (Tissue-Type Plasminogen Activator, Streptokinase and Urokinase' conducted by D.R. Musselman and others published in the 1994 issue of `American...
- FDA CLEARS THROMBOLYTIC DRUG FOR PHASE II CLINICAL TRIAL. // Worldwide Biotech;May2002, Vol. 14 Issue 5, p6
Reports on the approval by the U.S. Food and Drug Administration for the testing of British Biotech's novel thrombolytic agent, BB-10153, in heart attack patients.
- Intraoperative use of thrombolytic agents. Earnshaw, Jonothan J.; Beard, Jonathan // BMJ: British Medical Journal (International Edition);9/11/93, Vol. 307 Issue 6905, p638
Focuses on the use of intraoperative thrombolysis in the treatment of acute limb ischaemia. Ischemic neurosensory deficit in patients; Problems associated with streptokinase; Indications of thrombolysis; Need to develop a method to evaluate of intraoperative streptokinase.
- Eye on the Literature. // Formulary;May2002, Vol. 37 Issue 5, p230
Presents some published studies of interest to drug decision-makers. Effect of thrombolytics to elderly patients; Result of the hypericum perforatum test; Study on the effect of longer thromboembolism prophylaxis medication after surgery.
- Hormone replacement therapy: A kind of clot buster? // Patient Care;9/15/1996, Vol. 30 Issue 14, p177
Present an abstract of the article `Relation of Hormone Replacement Therapy to Measures of Plasma Fibrinolytic Activity,' by E. Shahar, A.R. Folsom, V.V. Salomaa et al taken from the 1996 `Circulation'.
- Editorial: Drugs in Interventional Cardiology. Radke, Peter W. // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1151
The article discusses various reports published within the issue, including one by Susanne Alban on the pharmacology of different antithrombotic drugs and another by Alexander Joost on anticoagulation problem in patients with confirmed or suspected heparin-induced thrombocytopenia (HIT).
- Current Clinical Use of Reteplase for Thrombolysis: A Pharmacokinetic-Pharmacodynamic Perspective. Martin, U.; Kaufmann, B.; Neugebauer, G. // Clinical Pharmacokinetics;1999, Vol. 36 Issue 4, p265
Clinical evaluation of a new thrombolytic agent should start with a dose that provides adequate efficacy and has an acceptably low bleeding risk; this results in a narrow therapeutic window at the upper end of the dose-response curve. Angiographic patency of the infarct-related artery is still...
- Fondaparinux Sodium: A Viewpoint by Alexander S. Gallus. Gallus, A.S. // Drugs;2002, Vol. 62 Issue 11, p1686
Presents the author's viewpoint on fondaparinux sodium (FS), a heparin-like material with pure anti-factor Xa and no anti-factor IIl activity. Bioavailability of FS; Possibility for FS to cause immune mediated thrombocytopenia.
- Fondaparinux Sodium: A Viewpoint by Alexander G. G. Turpie. Turpie, A.G.G. // Drugs;2002, Vol. 62 Issue 11, p1686
Presents the author's viewpoint on fondaparinux sodium (FS), a heparin-like material with pure anti-factor Xa and no anti-factor IIl activity. Advantages over heparins and other antithrombotic agents; Single molecular entity.